Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch
NCT03594162
No Longer Available
This protocol for compassionate use combines 2 different ways of fighting disease: antibodies and T cells. Both antibodies and T cells have been used to treat patients with cancers, and both have shown promise, but neither alone has been sufficient to cure most patients. This protocol combines both T cells and antibodies to create a more effective treatment. The investigational treatment is called autologous T lymphocyte chimeric antigen receptor cells targeted against the CD19 antigen (ATLCAR.C... Read More
Gender:
ALL
Ages:
Between 3 years and 70 years
Trial Updated:
12/02/2021
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina
Conditions: Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders
Register for Updates
Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
NCT02120157
Completed
This is a multi-institutional phase II haploidentical T cell replete bone marrow transplant (BMT) study in children with high-risk leukemia. The myeloablative conditioning regimen prescribed will be Total body irradiation (TBI)-based for lymphoid leukemia and busulfan-based for myeloid leukemia. Our goal is to establish an easily exportable, inexpensive platform for haplotransplantation that has a safety profile equivalent to matched related and unrelated BMTs. The primary objective will be to e... Read More
Gender:
ALL
Ages:
Between 6 months and 25 years
Trial Updated:
11/23/2021
Locations: Children's Hospital of Colorado, Aurora, Colorado +8 locations
Conditions: Myeloablative Conditioning, HLA-mismatched Bone Marrow Transplantation, Graft Survival, Transplantation, Bone Marrow
Register for Updates
Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer
NCT00629499
Completed
This is a non-randomized, Phase II study. Efficacy is not a primary endpoint in this study; however, progression-free survival will be followed and determined for the patients in this study. Approximately 50 patients are planned to be enrolled in this study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/23/2021
Locations: Watson Clinic Center for Cancer Care and Research, Lakeland, Florida +9 locations
Conditions: Breast Cancer
Register for Updates
Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer
NCT00866905
Completed
We propose to evaluate ixabepilone in combination with cyclophosphamide for the neoadjuvant treatment of locally advanced breast cancer. In this regimen, ixabepilone is substituted for docetaxel, since preclinical and clinical studies suggest that ixabepilone is more active than either docetaxel or paclitaxel. The combination of ixabepilone and cyclophosphamide could further improve the efficacy of non-anthracycline neoadjuvant therapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/18/2021
Locations: Aventura Medical Center, Aventura, Florida +19 locations
Conditions: Breast Cancer
Register for Updates
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
NCT00075582
Completed
This phase III trial is studying how well combination chemotherapy and radiation therapy work in treating patients with newly diagnosed low-risk rhabdomyosarcoma. Drugs used in chemotherapy, such as vincristine, dactinomycin, and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. It is not yet known which tr... Read More
Gender:
ALL
Ages:
49 years and below
Trial Updated:
11/17/2021
Locations: University of Alabama at Birmingham, Birmingham, Alabama +162 locations
Conditions: Adult Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Previously Untreated Childhood Rhabdomyosarcoma
Register for Updates
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
NCT00118209
Completed
This randomized phase III trial studies rituximab when given together with two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell non-Hodgkin's lymphoma. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/15/2021
Locations: Rebecca and John Moores UCSD Cancer Center, La Jolla, California +46 locations
Conditions: Large B Cell Lymphoma
Register for Updates
COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer
NCT04038489
Withdrawn
This study is designed to assess the safety and clinical activity of tamoxifen and the COX inhibitor, aspirin, given in combination with standard AC-T chemotherapy (doxorubicin, cyclophosphamide, and paclitaxel) for the treatment of high-risk estrogen receptor (ER)+, human epidermal growth factor receptor 2 (HER2)- breast cancer. If successful, the study could improve long-term outcomes for a subpopulation of women with aggressive stage I-III ER+/HER2- breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2021
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Breast Cancer, Estrogen Receptor-positive Breast Cancer
Register for Updates
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
NCT03168438
Terminated
This trial will evaluate safety, tolerability, and efficacy of letetresgene autoleucel (GSK3377794) with or without pembrolizumab in participants with relapsed and refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/09/2021
Locations: GSK Investigational Site, Duarte, California +4 locations
Conditions: Neoplasms
Register for Updates
Autologous Transplant for Multiple Myeloma
NCT00177047
Completed
This is a study of a regimen of melphalan and autologous stem cells for patients with multiple myeloma. We hypothesize that this particular regimen will improve the survival of these patients.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/07/2021
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Multiple Myeloma
Register for Updates
Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia
NCT00258427
Completed
RATIONALE: A bone marrow or umbilical cord blood transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. Giving combination chemotherapy before a donor stem cell transplant may make the transplant more likely to work. This may be an effective treatment for patients with high risk Fanconi's anemia. PURPOSE: This clinical trial is studying how well combination chemotherapy works in treating high risk patients who are undergoing a donor stem cell transplant for F... Read More
Gender:
ALL
Ages:
44 years and below
Trial Updated:
11/04/2021
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Fanconi Anemia
Register for Updates
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
NCT01777152
Completed
This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2021
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +143 locations
Conditions: Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma
Register for Updates
URMC Related Haplo-identical Donor BMT
NCT02660281
Completed
This study will be a single-center treatment protocol, designed to validate the process of related donor haploidentical-SCT at the Wilmot Cancer Institute Blood and Marrow Transplant Unit.
Gender:
ALL
Ages:
Between 6 months and 75 years
Trial Updated:
11/01/2021
Locations: Wilmot Cancer Institute, Rochester, New York
Conditions: Hematological Disease, Immune Deficiencies, Solid Tumors, Myelofibrosis, Multiple Myeloma, Lymphoma
Register for Updates